Fig. 5From: Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysisKaplan-Meier survival curve, time to treatment discontinuation in patients > 64 years old, OTX-101 vs. CsA. †P-value refers to the difference between treatments based on the log-rank test. CsA, cyclosporine ophthalmic emulsion 0.05%; OTX-101, cyclosporine ophthalmic solution 0.09%; TTD, time to treatment discontinuationBack to article page